Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 5/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 14/20 | 0.67 |
| ▸ | STS | P08842 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | ESR1 | P03372 | 2/20 | 0.67 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.67 |
| ▸ | SHBG | P04278 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | PGR | P06401 | 1/20 | 0.67 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | AR | P10275 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.67 |
| ▸ | SNCA | P37840 | 1/20 | 0.67 |
| ▸ | HTR2B | P41595 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12379610 | 1.00 | HSD17B1 (1.00) | HSD17B1CYP19A1STSLMNAESR1 | |
| SCHEMBL7176305 | 0.89 | HSD17B1 (0.80) | HSD17B1CYP19A1STSLMNAESR1 | |
| SCHEMBL12593631 | 0.88 | HSD17B1 (0.79) | HSD17B1CYP19A1STSLMNAESR1 | |
| SCHEMBL8205348 | 0.88 | HSD17B1 (0.79) | HSD17B1CYP19A1STSLMNAESR1 | |
| SCHEMBL7921186 | 0.86 | HSD17B1 (0.76) | HSD17B1CYP19A1STSLMNAESR1 | |
| SCHEMBL7921185 | 0.86 | HSD17B1 (0.76) | HSD17B1CYP19A1STSLMNAESR1 | |
| SCHEMBL2835007 | 0.85 | HSD17B1 (0.74) | HSD17B1CYP19A1STSLMNAESR1 | |
| SCHEMBL2564664 | 0.84 | HSD17B1 (0.72) | HSD17B1CYP19A1STSLMNAESR1 | |
| SCHEMBL12379608 | 0.83 | HSD17B1 (0.71) | HSD17B1CYP19A1STSLMNAESR1 | |
| SCHEMBL1981989 | 0.83 | HSD17B1 (0.71) | HSD17B1CYP19A1STSLMNAESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4391968-A1 | OCULAR DEVICE AND METHODS | Vinci Pharmaceuticals, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20230279170-A1 | CHIRAL-SUBSTITUTED POLY-N-VINYLPYRROLIDINONES AND COMPLEXES WITH BIMETALLIC NANOCLUSTERS AND USES THEREOF | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION | 2023-09-07 | — | — | US | disclosed |
| WO-2023028600-A1 | OCULAR DEVICE AND METHODS | VINCI PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2015161078-A1 | METHODS FOR COMPREHENSIVE PROFILING OF STEROID METABOLOME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-10-22 | — | — | WO | disclosed |
| US-8003783-B2 | Steroid 17 beta -hydroxysteroid dehydrogenase inhibitors substituted with one or more oxime groups, especially aromatase inhibitors used in the treatment of endocrine-dependent tumors, especially breast cancer | STERIX LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| EP-2336146-A1 | 17beta-hydroxysteroid dehydrogenase inhibitors | Sterix Limited (GB) | 2011-06-22 | — | — | EP | disclosed |
| CN-100526328-C | 17 beta-hydroxysteroid dehydrogenase inhibitors | STERIX LTD (GB) | 2009-08-12 | — | — | CN | disclosed |
| CN-1791611-A | 17beta-hydroxysteroid dehydrogenase inhibitors. | STERIX LTD (GB) | 2006-06-21 | — | — | CN | disclosed |
| US-20060074060-A1 | Compound | STERIX LIMITED (GB) | 2006-04-06 | — | — | US | disclosed |
| EP-1631579-A2 | 17BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Sterix Limited (GB) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004085457-A2 | 17BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | STERIX LIMITED (GB) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074060-A1 | Compound | HAT1, CBR3, ADH5 | HSD17B1 687/4885CYP19A1 1234/4885STS 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.